SAN DIEGO, June 18, 2014 /PRNewswire/ – CareFusion (NYSE:CFN), a leading global medical technology company, today announced the commercial launch of its new micro-laparoscopic line of surgical instruments, one of the most comprehensive lines available in the industry.
The CareFusion MicroLap offering is a reusable platform featuring a full line of hand instruments, access devices, scopes and accessories. With instruments as small as 2.7mm in diameter, these instruments leave an incision scar that is half that of standard (5mm or 10mm) laparoscopic instruments, eliminating the need to close the incision site with sutures in some procedures and resulting in a virtually scar-less procedure.
"With the trend of miniaturizing surgical procedures, the CareFusion MicroLap line of instruments offers the advantages of smaller incisions with high-quality instrument performance," said Andreas Lex, vice president and general manager for V. Mueller® and Snowden-Pencer® surgical instruments for CareFusion. "Smaller incisions provide the benefit of less patient discomfort and less scarring than with traditional 5mm or 10mm laparoscopic procedures."
The hand instrument offering consists of graspers, dissectors, scissors and needle holders. Hand instrumentation is made of a proprietary ceramic titanium alloy material to provide strength comparable to standard 5mm laparoscopic instruments. Scopes are available in 2.7mm and 2.9mm diameter options, with varying lens angles available. Also included in the line are electrosurgical options as well as suction and irrigation tools.
This full line enables surgeons to use the CareFusion MicroLap line for any type of laparoscopic surgery, with no limitations on specialty or procedural uses. It also offers a wide variety of jaw patterns and handle types, so surgeons don't have to compromise choice when switching to the CareFusion MicroLap line.
The new line of microlap instruments is manufactured by a Gimmi GmbH and CareFusion is the sole U.S. distributor.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.